|
[1] LANINI S,PISAPIA R,CAPOBIANCHI MR,et al. Global epidemiology of viral hepatitis and national needs for complete control[J]. Expert Rev Anti Infect Ther,2018,16(8):625-639.
|
|
[2] SUN YY,LIU HX,WANG N. Hepatitis C virus genotypes in China:A systematic review[J]. Chin J Epidemiol,2013,34(1):80-84.(in Chinese)苏迎盈,刘慧鑫,汪宁.中国丙型肝炎病毒基因型分布[J].中华流行病学杂志,2013,34(1):80-84.
|
|
[3] WONG MCS,HUANG JLW,GEORGE J,et al. The changing epidemiology of liver diseases in the Asia-Pacific region[J].Nat Rev Gastroenterol Hepatol,2019,16(1):57-73.
|
|
[4] CHEN YS,LI L,CUI FQ,et al. A sero-epidemiological study on hepatitis C in China[J]. Chin J Epidemiol,2011,32(9):888-891.(in Chinese)陈园生,李黎,崔富强,等.中国丙型肝炎血清流行病学研究[J].中华流行病学杂志,2011,32(9):888-891.
|
|
[5] COILLY A,ROCHE B,SAMUEL D. Current management and perspectives for HCV recurrence after liver transplantation[J].Liver Int,2013,33(Suppl 1):56-62.
|
|
[6] DOMNGUEZ-GIL B,MORALES JM. Transplantation in the patient with hepatitis C[J]. Transpl Int,2009,22(12):1117-1131.
|
|
[7] FORMAN LM,LEWIS JD,BERLIN JA,et al. The association between hepatitis C infection and survival after orthotopic liver transplantation[J]. Gastroenterology,2002,122(4):889-896.
|
|
[8] HEIDRICH B,PISCHKE S,HELFRITZ FA,et al. Hepatitis C virus core antigen testing in liver and kidney transplant recipients[J]. J Viral Hepat,2014,21(11):769-779.
|
|
[9] ALONSO R,PREZ-GARCA F,LPEZ-ROA P,et al. HCV core-antigen assay as an alternative to HCV RNA quantification:A correlation study for the assessment of HCV viremia[J]. Enferm Infecc Microbiol Clin,2018,36(3):175-178.
|
|
[10] FABRIZI F,AGHEMO A,MESSA P. Hepatitis C treatment in patients with kidney disease[J]. Kidney Int,2013,84(5):874-879.
|
|
[11] BURRA P,RODRGUEZ-CASTRO KI,MARCHINI F,et al.Hepatitis C virus infection in end-stage renal disease and kidney transplantation[J]. Transpl Int,2014,27(9):877-891.
|
|
[12] Kidney Disease:Improving Global Outcomes(KDIGO). KDIGO clinical practice guidelines for the prevention,diagnosis,evaluation,and treatment of hepatitis C in chronic kidney disease[J]. Kidney Int Suppl,2008(109):s1-s99.
|
|
[13] CIESEK S,PROSKE V,OTTO B,et al. Efficacy and safety of sofosbuvir/ledipasvir for the treatment of patients with hepatitis C virus re-infection after liver transplantation[J]. Transpl Infect Dis,2016,18(3):326-332.
|
|
[14] TERRAULT NA,STOCK PG. Management of hepatitis C in kidney transplant patients:On the cusp of change[J]. Am J Transplant,2014,14(9):1955-1957.
|
|
[15] LIN MV,SISE ME,PAVLAKIS M,et al. Efficacy and safety of direct acting antivirals in kidney transplant recipients with chronic hepatitis C virus infection[J]. PLo S One,2016,11(7):e0158431.
|
|
[16] KIEFFER TL,SARRAZIN C,MILLER JS,et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients[J].Hepatology,2007,46(3):631-639.
|
|
[17] FABRIZI F,MARTIN P,MESSA P. New treatment for hepatitis C in chronic kidney disease,dialysis,and transplant[J]. Kidney Int,2016,89(5):988-994.
|
|
[18] MORALES JM,FABRIZI F. Hepatitis C and its impact on renal transplantation[J]. Nat Rev Nephrol,2015,11(3):172-182.
|
|
[19] Kidney Disease:Improving Global Outcomes(KDIGO)Hepatitis C Work Group. KDIGO 2018 clinical practice guideline for the prevention,diagnosis,evaluation,and treatment of hepatitis C in chronic kidney disease[J]. Kidney Int Suppl,2018,8(3):91-165.
|
|
[20] XUE W,PAN D,YANG Y,et al. Molecular modeling study on the resistance mechanism of HCV NS3/4A serine protease mutants R155K,A156V and D168A to TMC435[J]. Antiviral Res,2012,93(1):126-137.
|
|
[21] WALKER A,FILKE S,LBKE N,et al. Detection of a genetic footprint of the sofosbuvir resistance-associated substitution S282T after HCV treatment failure[J]. Virol J,2017,14(1):106.
|
|
[22] World Health Organization. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection[R]. Geneva:World Health Organization,2018:1-83.
|
DownLoad: